CLL

ZYDELIG® for relapsed CLL
in combination with rituximab where rituximab alone is appropriate due to comorbidities

ZYDELIG + rituximab provided disease control in a phase 3 trial
Median PFS not reached (95% CI, 10.7 months-not reached)
vs 5.5 months (95% CI, 3.8-7.1) with rituximab alone; N=220

ZYDELIG is not indicated or recommended for first-line
treatment of any patient.

IDELALISIB + RITUXIMAB is a
SUGGESTED TREATMENT REGIMEN in the NCCN Clinical Practice Guidelines
in
Oncology (NCCN Guidelines®) for
appropriate patients with relapsed/refractory CLL.1*

*In patients for whom rituximab monotherapy would be considered appropriate due to comorbidities, renal impairment, and/or grade ≥3 cytopenias due to prior therapy. Please see the complete version of the NCCN Guidelines® for Non-Hodgkin's Lymphomas available on NCCN.org for specific recommendations.

CI=confidence interval; CLL=chronic lymphocytic leukemia; NCCN®=National Comprehensive Cancer Network®; PFS=progression-free survival.